JDMAX
Price
$145.38
Change
-$1.24 (-0.85%)
Updated
Aug 20 closing price
Net Assets
21.85B
NBMBX
Price
$15.23
Change
+$0.15 (+0.99%)
Updated
Aug 21 closing price
Net Assets
2.23B
Interact to see
Advertisement

JDMAX vs NBMBX

JDMAX vs NBMBX Comparison Chart in %
View a ticker or compare two or three
VS
JDMAX vs. NBMBX commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JDMAX is a Hold and NBMBX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
JDMAX has more cash in the bank: 21.8B vs. NBMBX (2.23B). JDMAX (0.00) and NBMBX (0.00) have matching dividends . JDMAX was incepted earlier than NBMBX: JDMAX (17 years) vs NBMBX (30 years). NBMBX (1.18) and JDMAX (1.14) have similar cost to investors . NBMBX is a more actively managed with annual turnover of: 144.00 vs. JDMAX (17.00). NBMBX has a lower initial minimum investment than JDMAX: NBMBX (0) vs JDMAX (2500). JDMAX annual gain was more profitable for investors over the last year : 4.44 vs. NBMBX (-18.65). JDMAX return over 5 years is better than : -13.55 vs. NBMBX (-32.05).
JDMAXNBMBXJDMAX / NBMBX
Total Expense Ratio1.141.1897%
Annual Report Gross Expense Ratio1.141.1897%
Fund Existence17 years30 years-
Gain YTD9.3084.101227%
Front Load6%N/A-
Min. Initial Investment25000-
Min. Initial Investment IRAN/AN/A-
Net Assets21.8B2.23B977%
Annual Yield % from dividends0.000.00-
Returns for 1 year4.44-18.65-24%
Returns for 3 years16.987.83217%
Returns for 5 years-13.55-32.0542%
Returns for 10 years56.0612.40452%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPXX19.080.09
+0.47%
Nuveen S&P 500 Dynamic Overwrite Fund
FBDC17.67N/A
-0.01%
FT Confluence BDC & SpecialtyFinacIncETF
CALI50.38-0.01
-0.03%
iShares Short-Term CA Muni Act ETF
WEA10.43-0.05
-0.48%
Western Asset Premier
BIS10.82-0.30
-2.70%
ProShares UltraShort Nasdaq Biotech